Your browser is no longer supported. Please, upgrade your browser.
Settings
KLDO [NASD]
Kaleido Biosciences, Inc.
Index- P/E- EPS (ttm)-2.35 Insider Own3.92% Shs Outstand42.54M Perf Week-10.53%
Market Cap198.46M Forward P/E- EPS next Y-2.40 Insider Trans0.00% Shs Float38.74M Perf Month-21.91%
Income-90.10M PEG- EPS next Q-0.55 Inst Own81.70% Short Float6.78% Perf Quarter-17.54%
Sales1.20M P/S165.38 EPS this Y27.40% Inst Trans0.02% Short Ratio18.55 Perf Half Y-41.53%
Book/sh1.18 P/B3.75 EPS next Y-6.70% ROA-112.00% Target Price- Perf Year-36.59%
Cash/sh1.60 P/C2.76 EPS next 5Y- ROE-201.90% 52W Range4.51 - 20.50 Perf YTD-51.43%
Dividend- P/FCF- EPS past 5Y- ROI-190.10% 52W High-78.44% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low-2.00% ATR0.32
Employees82 Current Ratio6.10 Sales Q/Q-33.30% Oper. Margin- RSI (14)32.60 Volatility6.09% 6.31%
OptionableYes Debt/Eq0.43 EPS Q/Q5.40% Profit Margin- Rel Volume0.84 Prev Close4.69
ShortableYes LT Debt/Eq0.35 EarningsAug 11 BMO Payout- Avg Volume141.59K Price4.42
Recom2.30 SMA20-15.28% SMA50-21.71% SMA200-43.11% Volume119,630 Change-5.76%
Oct-19-21Downgrade Morgan Stanley Equal-Weight → Underweight $3
Feb-09-21Initiated Piper Sandler Overweight $19
Dec-23-20Initiated JMP Securities Mkt Outperform $22
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
Apr-23-19Initiated Chardan Capital Markets Buy $17.50
Mar-25-19Initiated Morgan Stanley Overweight $17
Mar-25-19Initiated JP Morgan Neutral $15
Mar-25-19Initiated Goldman Buy $20
Oct-13-21 10:00AM  
Oct-12-21 07:30AM  
Oct-05-21 02:30PM  
12:15PM  
08:01AM  
07:00AM  
Sep-29-21 07:30AM  
Sep-23-21 09:48AM  
Sep-07-21 01:20PM  
Sep-02-21 07:30AM  
Aug-11-21 08:55AM  
07:30AM  
Aug-10-21 07:30AM  
Aug-09-21 04:15PM  
Aug-06-21 07:30AM  
Jul-27-21 03:03PM  
Jun-30-21 10:08AM  
Jun-10-21 07:30AM  
Jun-03-21 04:32AM  
May-25-21 06:00AM  
May-19-21 09:01AM  
May-04-21 07:30AM  
Apr-20-21 07:30AM  
Apr-15-21 07:30AM  
Apr-06-21 02:43PM  
Apr-01-21 12:24PM  
Mar-31-21 01:33PM  
Mar-30-21 09:30AM  
Mar-25-21 06:10PM  
Mar-24-21 08:34AM  
07:00AM  
07:00AM  
Mar-03-21 07:35AM  
Mar-01-21 07:30AM  
Feb-11-21 01:11PM  
Feb-09-21 10:09AM  
02:50AM  
Feb-03-21 10:03PM  
04:10PM  
Jan-20-21 07:30AM  
Jan-14-21 07:30AM  
Jan-05-21 07:30AM  
Jan-04-21 07:30AM  
Dec-23-20 10:07AM  
Nov-24-20 03:00PM  
Nov-13-20 09:23AM  
Nov-02-20 07:35AM  
Oct-23-20 07:31AM  
Oct-07-20 07:30AM  
Oct-06-20 07:30AM  
Oct-02-20 12:09PM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-09-20 07:00AM  
Aug-27-20 07:00AM  
Aug-06-20 11:26AM  
Aug-05-20 08:00AM  
Aug-04-20 07:35AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jun-16-20 04:45PM  
Jun-08-20 08:30AM  
Jun-07-20 08:54AM  
Jun-04-20 08:30AM  
Jun-01-20 09:30PM  
04:17PM  
May-28-20 08:00AM  
May-27-20 03:14PM  
May-14-20 06:32AM  
06:30AM  
May-12-20 08:30AM  
Apr-03-20 08:30AM  
Mar-31-20 11:30AM  
Mar-02-20 07:35AM  
Jan-09-20 08:00AM  
Jan-06-20 08:30AM  
Dec-22-19 01:52PM  
Dec-19-19 08:00AM  
Dec-12-19 08:00AM  
Nov-06-19 08:00AM  
Nov-05-19 01:36PM  
Oct-30-19 04:05PM  
Oct-25-19 04:44PM  
Oct-22-19 08:00AM  
Oct-03-19 08:00AM  
Sep-30-19 08:00AM  
Sep-27-19 07:56AM  
Sep-26-19 04:10PM  
Sep-09-19 07:30AM  
Sep-03-19 08:00AM  
Aug-29-19 08:00AM  
Aug-08-19 06:38AM  
Aug-01-19 07:30AM  
Jul-31-19 08:00AM  
Jul-22-19 08:00AM  
Jul-18-19 03:42PM  
Jul-15-19 08:00AM  
Jun-26-19 08:00AM  
Jun-03-19 08:00AM  
May-08-19 02:23PM  
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund IV Gene10% OwnerFeb 08Buy11.50215,0002,472,5002,982,639Feb 10 05:30 PM